Acute graft-versus-host disease (aGVHD) was noted as a complication of allogeneic bone marrow (BM) transplantation in animal models more than six decades ago (1, 2). The initial descriptions of aGVHD differentiated it from the complications of BM aplasia and focused on the severe consequences of GVHD for lower gastrointestinal (GI) tract function, as manifested by weight loss and profound diarrhea. Subsequent studies clearly identified donor T cells as the critical cells required for the induction of aGVHD (3)(4)(5). aGVHD was shown to predominantly involve the skin, liver, and lower GI tract and, later, the upper GI tract (6). In the absence of approaches to prevent aGVHD, this complication occurs in close to 100% of recipients of allogeneic BM/stem cell transplants (allogeneic hematopoietic cell transplantation, allo-HCT), greatly limiting the survival of the first cohort of patients who underwent allo-HCT.
Immune homeostasis in the GI tract
The immune balance of the human small intestine and colon is complex. There are over 100 trillion bacteria that are critical to the function of the GI tract, and individuals are exposed to a huge number of food-borne antigens on a daily basis. Thus, there must exist dynamic and robust mechanisms that mediate immune responses to pathogenic organisms but that prevent immune responses to normal flora and dietary antigens.
Antigen-presenting cells in the GI tract. Specialized hematopoietic antigen-presenting cells (APCs) in the GI tract include multiple subpopulations of dendritic cells (DCs) and macrophages ( Figure  1 ). DCs in the lamina propria (LP) and Peyer's patch sample luminal antigens and migrate to regional lymph nodes (LNs) to activate immune responses (13, 14) . Macrophages are sessile and are the most abundant innate immune cells in the intestine; they maintain homeostasis by phagocytosing microorganisms and apoptotic Lower gastrointestinal (GI) tract graft-versus-host disease (GVHD) is the predominant cause of morbidity and mortality from GVHD after allogeneic stem cell transplantation. Recent data indicate that lower GI tract GVHD is a complicated process mediated by donor/host antigenic disparities. This process is exacerbated by significant changes to the microbiome, and innate and adaptive immune responses that are critical to the induction of disease, persistence of inflammation, and a lack of response to therapy. Here, we discuss new insights into the biology of lower GI tract GVHD and focus on intrinsic pathways and regulatory mechanisms crucial to normal intestinal function. We then describe multiple instances in which these homeostatic mechanisms are altered by donor T cells or conditioning therapy, resulting in exacerbation of GVHD. We also discuss data suggesting that some of these mechanisms produce biomarkers that could be informative as to the severity of GVHD and its response to therapy. Finally, novel therapies that might restore homeostasis in the GI tract during GVHD are highlighted. Homeostasis is maintained, in part, by large numbers of commensal bacteria that stimulate IL-22 production by ILC3s. Commensal bacteria also produce metabolites such as butyrate, which promote the health of Tregs, as well as enterocytes and ILC2s, which maintain antiinflammatory myeloid-derived suppressor cells (MDSCs) and enhance GI barrier function. During allo-HCT, ILC2s are eliminated by hematopoietic cell transplant (HCT) conditioning, resulting in diminished antiinflammatory properties in the GI tract. However, ILC3s, which secrete IL-22 that protects ISCs and induces regenerating family member 3α (REG3) in Paneth cells, resist host conditioning. REG3 is concentrated in the mucus that shields the sterile surfaces of enterocytes from potential pathogens present in the intestinal microbiome. After allo-HCT, donor conventional T cells (Tcons) recognize histocompatibility antigens on both hematopoietic (HP) and non-HP APCs. Activated Tcons proliferate and trigger release of alarmins, such as IL-33 and its soluble receptor ST2, from non-HP APCs, such as stromal cells and endothelium; these activated Tcons also express the integrin receptor α 4 β 7 , which directs their migration back to intestinal tissue after entering the villus capillaries. the absence of CD73 on either donor T cells or host APCs exacerbated GVHD (54) (55) (56) . UA, a purine metabolite released from damaged cells, is an endogenous DAMP that stimulates DCs and activates CD8 + T cell cytotoxic functions (45, 57) . Recent data show that UA contributes to GVHD severity by stimulating the NLRP3 inflammasome (57, 58) . HMGB1 is a ubiquitous DNA-binding nuclear protein found in all eukaryotic cells that binds to nucleosomes and regulates gene transcription (46) . It is released from damaged tissues and binds to PRRs such as TLR2, TLR4, and the receptor for advanced glycation end products (RAGE) (46, (59) (60) (61) (62) . Increased HMGB1 is observed in recipient mice after experimental allo-HCT (60) , and treatment of hosts with indole-derived antioxidant mitigates the release of ROSdependent HMGB1 and reduces severity of GI tract GVHD (63) . Consistent with murine data, an increase in serum levels of HMGB1 has been observed in patients with aGVHD (64), but these levels have not yet been correlated directly with the severity of GI tract GVHD.
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Alarmins can both induce and suppress immune responses in the GI tract. Receptors with immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or ITIM-like regions in their intracellular domains regulate DAMP-mediated innate inflammatory responses (65) (66) (67) (68) and belong to the family of sialic acid-binding immunoglobulinlike lectins (Siglecs) (68) . Siglec-G expression in host APCs plays an important role in protecting against DAMP-mediated GVHD due to tissue damage following conditioning (69, 70) . Siglec-G interacts with its ligand CD24, a glycosylphosphatidylinositol-anchored glycoprotein expressed by T cells. Interestingly, CD24 negatively regulates DAMPs such as HMGB1 through a direct interaction of a trimolecular complex composed of Siglec-G, CD24, and HMGB1 (70) . The interaction of Siglec-G with CD24 has been shown to limit the severity of GVHD in animal models (46) . Furthermore, enhancing Siglec-G-CD24 activity using a novel CD24 fusion protein (CD24Fc) mitigated GVHD in multiple experimental BM transplant (BMT) models (70) .
α 1 -Antitrypsin. α 1 -Antitrypsin (AAT), a serine protease inhibitor predominantly generated in the liver, possesses antiinflammatory properties that enhance the generation of IL-10 and TGF-β and reduce the generation of IL-6 by APCs (71) . An initial role for AAT in the biology of GVHD came from studies indicating that it decreased IL-32 production in mixed lymphocyte responses (72) . AAT treatment of recipient mice in a minor-mismatched GVHD model diminished GI tract inflammation, decreased generation of proinflammatory cytokines and effector cells, increased generation of Tregs and host APC IL-10 production, and improved survival (73) .
Inflammasomes and GI tract GVHD
Inflammasomes such as NLRP2, NLRP3, and NLRP6 are large cytosolic complexes that sense DAMPs and activate caspase-1 and -11, resulting in the production of the proinflammatory cytokines IL-1β and IL-18 (74) . NLRP3 activation enhanced GVHD (57, 58) , and donor NLRP3 polymorphisms have been associated with outcomes after allo-HCT (75) . Two genetic variants in donor NLRP3 were associated with an increased risk of disease relapse (75) . An increased risk for grades III-IV aGVHD was found in recipients with the NLRP2 CC genotype compared with CA/AA (75) . Additionally, 2 genetic variants in NLRP2 in both donor and patient were associated with inferior nonrelapse mortality and survival (75) . NLRP6 is expressed that migrate to the small intestine in response to CCL25 generated by small bowel endothelial cells and stromal cells in the LP and intestinal crypts (28, 29) .
Innate lymphoid cells. Mature T and B lymphocytes require the rearrangement of germline-encoded receptors to become specific for individual antigens (30) . Research in the past decade has discovered a group of innate lymphoid cells (ILCs) that lack antigenspecific receptors and are present in mucosal sites such as the lung and GI tract (31, 32) 
GVHD and innate immunity
Alarmins. The homeostatic and regulatory mechanisms that limit GI tract inflammation to commensal flora or food-borne antigens are often targets during GVHD. Preparative chemo-radiation regimens for allo-HCT damage both host epithelium and hematopoietic cells (34) . GI tract damage in patients undergoing allo-HCT is exacerbated via the release of inflammatory mediators from conditioning therapy. The GI damage caused by the conditioning regimens releases alarmins, including danger-associated molecular patterns (DAMPs), microbe-associated molecular patterns (MAMPs), and inflammatory cytokines (34) (35) (36) . MAMPs interact with specific pattern recognition receptors (PRRs) (37) (38) (39) (40) ; the stimulation of these receptors results in initiation and/or amplification of immune responses, triggers inflammation, and leads to tissue destruction and, occasionally, repair (41) . Alarmins are the bestcharacterized DAMPs and include HSPs, high-mobility group box 1 (HMGB1), purine metabolites, uric acid (UA) crystals, histones, mitochondria, components of extracellular matrix heparan sulfate proteoglycans, syndecans, fibronectin, and inflammatory cytokines including IL-33 (refs. 38-40, 42-48, and Figure 1 ). Herein, we will focus on DAMP alarmins and their role in GI GVHD.
ATP is released from damaged cells and binds to the P2X family of purinergic receptors, including P2X7 and P2Y2 (49) (50) (51) . ATP engagement of P2X7 on host hematopoietic APCs enhanced their activation, amplified stimulation of the alloreactive donor CD4 + T cells, and enhanced Th1 responses (50) , whereas interruption of this pathway decreased GI tract GVHD (50) . Systemic administration of broad-spectrum P2X7 antagonists attenuated GVHD (50, 52) . Likewise, GVHD was mitigated by the absence of another ATP purinergic receptor, P2Y2, on the host hematopoieticderived APCs (51) . Increased extracellular ATP is regulated by ectonucleotidases such as CD73 (ecto-5-nucleotidase), which converts AMP to adenosine (53) . Treatment of recipient mice with adenosine A 2A receptor agonists decreased GVHD, whereas
The Journal of Clinical Investigation Neutrophils are professional phagocytic cells that possess a vast array of antimicrobial functions allowing for rapid clearance of bacterial pathogens (87) . A role of neutrophils in the pathogenesis of aGVHD has been demonstrated, as total-body irradiation led to an increase in the migration of neutrophils to the GI tract dependent on the presence of microbial flora in the ileum (88) . Transfer of TLR-expressing neutrophils enhanced GVHD mortality compared with the decreased mortality found after the transfer of TLR-deficient neutrophils. The transfer of BM cells lacking SMAD3, a critical signaling component of the TGF-β axis, greatly increased GVHD lethality, which correlated with enhanced Th1 polarization of donor T cells and neutrophil recruitment to the GI tract, mesenteric LNs, and spleen (89) . Depleting myeloid cells using anti-Gr-1 mAb therapy greatly improved the outcome of mice receiving SMAD-deficient BM (89).
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Microbiome and GI GVHD
Forty years ago, van Bekkum and Knaan reported that germ-free mice had minimal GVHD (90) . This observation led to widespread use of antibiotics to "decontaminate" the GI tract before and during allo-HCT. Initial studies of antibiotics to decontaminate the GI tract suggested promising results (91, 92) , but other studies demonstrated no benefit with broad-spectrum antibiotics. By contrast, a recent analysis demonstrated that broad-spectrum antibiotic use, specifically agents with activity against anaerobes such as imipein intestinal epithelial cells (IECs) and regulates epithelial homeostasis and the gut microbiome (69, 76) . NLRP6 deficiency improved GVHD, but exacerbated experimental inflammatory bowel disease (76, 77) . Further, BM chimera experiments have suggested a role for nonhematopoietic expression of NLPR6 in GI tract GVHD (48).
APCs and GI tract GVHD
Host APCs are key to the induction of GVHD (78, 79) . Earlier studies that primarily used adoptive transfer approaches demonstrated 
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2 4 4 5 jci.org Volume 127 Number 7 July 2017 (93) . These data support the hypothesis that GI microbial taxonomy impacts the severity of GVHD through effects on adaptive immune responses and/or target tissues.
Inflammatory cytokines
Inflammatory cytokines synergize with cytotoxic T cells to amplify local tissue injury and promote inflammation, which ultimately leads to target tissue destruction in the BMT recipient (110) . Th1 cytokines (IFN-γ, IL-2), TNF, and IL-6 have often been implicated in the cytokine storm that occurs early after BMT and have been shown to be critical for the pathophysiology of aGVHD (111) (112) (113) . In addition to IL-2, several other common γ chain cytokines (IL-21, IL-7, and IL-15) play a critical and potentially nonredundant role in GVHD pathogenesis (114) . Tc1/Th1 maturation is recognized as the dominant pattern in aGVHD (115, 116) . Increased quantities of the Th1 cytokines TNF and IFN-γ are associated with early onset of aGVHD and more severe disease in both preclinical models and clinical BMT. Th2 and Th17 subsets may also mediate GVHD pathology, and the balance between subsets determines aGVHD severity in various target organs (117) (118) (119) (120) . Th17 differentiation is initiated by IL-6 (121) with RORγt as the defining transcription factor, whereas maintenance and amplification of these cells rely on IL-23 and IL-21, respectively. The use of RORC-deficient donor T cells attenuates aGVHD severity and lethality (122) , and the elimination of hyperinflammatory Tc17 early after BMT reduces GI GVHD and improves survival without diminishing graft-versusleukemia effects (123) . Recent data suggest that IL-6 is a critical cytokine that increases GVHD severity. It has direct cytopathic effects on the GI tract following allogeneic BMT and likely inhibits the suppressive function of Tregs (113) . IL-6 and the Th17/Tc17 pathway play a critical role in the microbial ecology after allo-BMT. Mice lacking IL-17A, IL-17F, or their receptors developed significant GI tract GVHD, which correlated with microbial dysbiosis (124) . IL-23, generated by donor APCs, has been shown to play a critical role in the induction of GVHD in the lower GI tract (125) . Recently, a population of CD4 + T cells that coexpresses the IL-23 receptor, CD11c, and innate cell TLR and NLR proteins was shown to be critical to the induction of GI GVHD by IL-23. IL-10 generated by non-Tregs was critical in controlling inflammation by these cells (126) .
IL-33, a member of the IL-1 family, has generated particular interest because soluble ST2, a decoy receptor for IL-33, is a blood biomarker for steroid-resistant GVHD (127) . During GVHD, IL-33 levels increase dramatically in the GI tract, especially IL-33 produced by nonhematopoietic cells such as endothelial cells and stroma (Figure 2 and ref. 128 ). Mice that are deficient in IL-33 experience less severe GVHD, and donor T cells that lack the membrane-bound IL-33 receptor mST2 generate less IFN-γ and TNF compared with their WT counterparts, leading to reduced GVHD. Blockage of IL-33/ST2 interactions can also protect mice from lethal GVHD (128). As noted above, IL-33 can be classified as an alarmin, and the damaged tissue that releases IL-33 also secretes soluble ST2 (129) . However, IL-33 has pleiotropic effects, and administration of IL-33 prior to BMT can drive proliferation of Tregs and ILC2s (our unpublished data) that prevent experimental GVHD (130) . Thus, the effect of therapeutic strategies to manipulate the IL-33/ST2 axis in clinical HCT may not be straightforward.
nem/cilastatin and piperacillin/tazobactam, was associated with increased GVHD-related mortality. In contrast, cefepime and aztreonam, which have very limited anaerobic activity, were not associated with GVHD-related mortality (93) . Interestingly, prophylaxis with rifaximin, a nonabsorbed broad-spectrum oral antibiotic, was associated with a decrease in Enterococcus species, higher levels of urinary 3-indoxyl sulfate, which is associated with the presence of Clostridiales, and improved survival compared with ciprofloxacin and the antianaerobic antibiotic metronidazole (94) .
Experimental models have shown a persistent loss of GI microbial diversity in animals with GVHD (95, 96) , and the magnitude of the loss correlated with treatment-related mortality after allo-HCT (97) . Loss of commensals such as Blautia and Lactobacillus is associated with the overgrowth of pathogens such as Proteobacteria and Enterococcus, which correlates with GI GVHD (93, (97) (98) (99) . It is not yet clear whether antibiotic dysbiosis is a primary or secondary phenomenon in GVHD. In support of the former, the microbiota seems to be influenced by the host's genotype; in support of the latter, infections, antibiotics, drugs, and diet can all induce dysbiosis (100). The fundamental question of whether dysbiosis alone is sufficient to cause GVHD remains to be answered.
Microbial metabolites and GI GVHD. The microbiota metabolizes material directly ingested by the host, producing its own metabolites. The intestinal metabolome therefore consists of products from discrete host metabolism, microbial metabolism, and mammalian/microbial cometabolism (101) . The impact of microbiotaderived metabolites is increasingly appreciated in intestinal homeostasis (101). Short-chain fatty acids (SCFAs) are the most thoroughly studied microbial metabolites and are absorbed by the intestinal epithelium following the fermentation of complex polysaccharides in the gut (100, 101). The SCFA butyrate is the major energy source for IECs (100, 101) . In one study, the concentration of butyrate was significantly decreased in intestinal tissue after allo-HCT, although the concentrations of other SCFAs were not significantly changed in either serum or tissues (102) . Reduced butyrate in CD326 + IECs after allo-HCT contributed to decreased histone acetylation, which was restored after local administration of exogenous butyrate, resulting in improved IEC junctional integrity, increased antiapoptotic proteins, decreased GVHD, and improved survival (102) . Additionally, alteration of the indigenous microbiota with 17 rationally selected strains of high-butyrateproducing Clostridia species also decreased GI tract GVHD and increased survival after allo-HCT (102-104).
The expression of indoleamine dioxygenase (IDO) is increased in intestinal cells and APCs after allo-HCT (105, 106) . High IDO expression depletes tryptophan, resulting in apoptosis of alloreactive donor T effectors and generation of iTregs (107, 108) . Aside from these direct immune regulatory activities, IDO-generated tryptophan by-products may also suppress GVHD directly (89) . Clinical studies showed that lower levels of urinary 3-indoxyl sulfate, an indole metabolite influenced by commensal bacteria, correlated with decreased patient survival after allo-HCT (109) . A recent clinical study showed an association between GVHD, the need for parenteral nutrition, the loss of microbial diversity, and reduced levels of Blautia (98) . In mouse models, antibiotic treatment worsened GVHD, increased gut damage, and was associated with increased Akkermansia, a mucus-devouring microbe (Figure 2 and ref. 132) . Loss of commensal bacteria leads to diminished intestinal microbial diversity that is observed in both experimental and clinical GVHD (95) . The principal inducer of REG3 in both Paneth cells and other enterocytes is IL-22, which is produced by ILC3s (Figure 2) . Administration of IL-22 induces REG3 and protects ISCs, preventing a breach in the GI epithelial barrier and reducing GI GVHD (133) . Paneth cell loss probably reflects the loss of ISCs, which are not readily visible by standard histologic techniques (134) .
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ILC3s. ILC3s constitute a very heterogeneous population of immune cells with inherent plasticity. There are multiple different lineages of ILC3s, and one approach to classifying these cells is based on expression of the chemokine receptor CCR6. CCR6 + ILC3s can be subdivided into those that express CD4, while CCR6 A second approach to enhance the function of ISCs in the GI tract was demonstrated using the potent WNT signaling activator R-spondin-1. WNT activation is critical to the persistence of ISCs (136) . Administration of R-spondin-1 to mice undergoing allo-BMT significantly decreased the production of TNF and IFN-γ, reduced the expansion of proinflammatory donor T cells, and improved overall survival in comparison with control-treated animals (137) .
ILC2s. In contrast to the persistence of host ILC3s after conditioning therapy, recent work demonstrated that ILC2s in the LP were markedly depleted by both irradiation and cytotoxic chemotherapy and did not recover significantly from donor BM cells (138) . Interestingly, ILC2s in the lung were not depleted by either treatment. The administration of ex vivo-expanded ILC2s markedly diminished aGVHD in the lower GI tract with improvement in survival with infusion on day 0 (preventative) or day 7 (treatment) (138) . Infusion of donor ILC2s significantly decreased the generation of proinflammatory donor T cells in the colon and small bowel, which was associated with enhanced numbers of donor myeloid-derived suppressor cells in the lower GI tract. The antiinflammatory effects of ILC2s were dependent on their generation of IL-13, while production of amphiregulin by donor ILC2s was required for maintenance of the epithelial barrier after transplant.
Clinical studies
ILCs in GVHD.
There is increasing evidence of a potential role for ILCs in patients after allo-HCT. Circulating ILC2s are diminished after both chemotherapy and allo-HCT (139) . Twelve weeks after transplant there was a significant decrease in ILC2s with a more modest but significant decrease in ILC1s and NCR -ILC3s. By contrast, NCR + ILC3s were significantly increased. Patients with increased proportions of activated (CD69 + ) ILCs prior to transplant had a significantly reduced incidence of aGVHD and mucositis. Additionally, patients with an increased number of α 4 β 7 + ILC2s and/or NCR -ILC3s prior to transplantation had a diminished incidence of aGVHD of the lower GI tract.
Another group of investigators evaluated the recovery of ILCs after allo-HCT (140). They found that ILC numbers decreased in older individuals and were greatest in cord blood products. Patients with severe combined immunodeficiency, which included JAK3 or IL-2Rγ mutations (ILCs are absent in patients with IL-2Rγ mutations), who received nonmyeloablative conditioning had almost no detectable ILC2s or ILC3s in the bloodstream after transplant. Similarly, a subset of these patients had a significant deficiency in NCR + ILCs in the skin and GI tract after transplant. This was not found in pediatric patients undergoing myeloablative conditioning for the treatment of leukemia, indicating an ability to reconstitute ILCs from pediatric donors but only after myeloablative conditioning. The authors demonstrated impaired recovery of donor-derived ILC2s and ILC3s in mice after nonmyeloablative compared with myeloablative conditioning and syngeneic BMT, confirming clinical data showing that ILC2s and ILC3s are poorly regenerated from donor BM, especially after nonmyeloablative conditioning therapy. These data suggest that the reconstitution of peripheral ILCs, especially ILC2s and NCR -ILC3s from adult donor BM and/or peripheral blood stem cells, or from pediatric donors after nonmyeloablative conditioning, may be suboptimal.
Biomarker evaluations. Soluble ST2 levels are elevated in the blood early after allo-HCT, and an algorithm using both ST2 and REG3 concentrations has been validated to predict lethal GVHD 7 days after transplant in a very large (1,287 patients) multicenter data set (141) . REG3 emerged from an unbiased proteomic screen to identify plasma biomarkers specific for GI GVHD, and in a multicenter data set of more than 1,000 patients, blood levels of REG3 increased fourfold in patients with lower GI tract GVHD but not in patients with enteritis from other causes (142) .
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The degree of REG3 elevation also predicted clinical response to GVHD therapy and correlated with increased Paneth cell loss, suggesting that increased levels reflected damage in the GI tract (142) . A further analysis of BMT patients demonstrated that the loss of Paneth cells in biopsies was positively correlated with the clinical severity of GI tract GVHD (143) . The number of Paneth cells inversely correlated with eventual response to treatment for GVHD and with nonrelapse mortality, which was primarily from GI tract GVHD. Therapeutic approaches. While many of the findings in this Review are quite early in development and have yet to be translated, there are novel therapies that have emerged from our enhanced understanding of GI tract biology (Table 1) . Significant responses to AAT have been observed in small, single-center, phase I/II trials for the treatment of steroid-refractory GVHD (144) . AAT is currently being evaluated in a multi-institutional clinical trial as therapy for steroid-refractory lower GI tract GVHD (NCT02956122, ClinicalTrials.gov). Numerous investigators are evaluating whether reconstitution of a diverse microbiome can reduce GI tract GVHD via either stool transplantation, the administration of specified types of bacteria, the administration of compounds that alter the microbiome (NCT02763033), or allo-HCT out of the hospital (NCT01725022). The role of IL-22 in the maintenance of ISCs and the generation of REG3 has led to a clinical trial (NCT02406651) using F-652 with steroids for the treatment of patients with new-onset grades II-IV aGVHD of the lower GI tract.
The critical role for IL-6 in the biology of aGVHD was recently demonstrated in a phase I/II trial of 48 patients using the IL-6 receptor-targeted mAb tocilizumab (8 mg/kg) 1 day before allo-HCT from HLA-identical siblings along with standard calcineurin inhibition and methotrexate (145) . The incidence of grades II-IV GVHD at day 100 was 12%; the incidence of grades II-IV GI tract GVHD was 8%. Overall survival was 84% at 24 months with 68% of patients experiencing relapse-free survival. A phase III trial currently in progress should definitively address the ability of tocilizumab to prevent aGVHD (www.cancertrialsaustralia.com/Clinical-Trials-Register. aspx; ACTRN12614000266662).
Conclusions
Control of inflammation in the GI tract is an extremely complex process requiring intricate interactions between innate and adaptive immune cells, APCs, epithelia, stroma, and the microbiome, and the consequent generation of alarmins, cytokines, effector cells, and other mediators of inflammation. The activation of donor T cells by host cells in the GI tract perturbs many of these processes, generating alarmins and cytokines that enhance the proinflammatory activity of innate immune cells and that inhibit local immunosuppressive pathways. Donor T cells mediate the loss of ILC3s, leading to diminished numbers of ISCs and decreased function of Paneth cells through decreased production of antibacterial peptides. Conditioning therapy leads to loss of ILC2s and diminished antiinflammatory properties in the GI tract with impaired barrier repair. Finally, all of these processes alter (161) (162) (163) Reduces number/function of proinflammatory donor T cells Ex vivo administration of MDSCs Donor/third-party Tregs (164) (165) (166) (167) Enhances number of Tregs in the GI tract Ex vivo administration of donor/third-party Tregs Donor/third-party MSCs (168, 169) Induces APC production of IL-10 and prostaglandin E 2 and decreases proinflammatory T cells
Ex vivo administration of third-party MSCs
MDSC, myeloid-derived suppressor cell; MSC, mesenchymal stem cell.
The Journal of Clinical Investigation the microbiome, leading to changes in metabolites and the diminished function of immunosuppressive mechanisms and cells such as Tregs. Our increased understanding of this complex system has led to a new understanding of GI GVHD as a failure to reconstitute normal mucosal immunity that ultimately results in the loss of critical ISCs, crypt damage, and disruption of the GI tract epithelial barrier. This new focus on the interactions between the innate and the adaptive immune system has led to new and unexpected approaches to therapeutic strategies. 
